Literature DB >> 22593170

A single mutation in the glycophorin A binding site of hepatitis A virus enhances virus clearance from the blood and results in a lower fitness variant.

M Isabel Costafreda1, Enric Ribes, Angels Franch, Albert Bosch, Rosa M Pintó.   

Abstract

Hepatitis A virus (HAV) has previously been reported to bind to human red blood cells through interaction with glycophorin A. Residue K221 of VP1 and the surrounding VP3 residues are involved in such an interaction. This capsid region is specifically recognized by the monoclonal antibody H7C27. A monoclonal antibody-resistant mutant with the mutation G1217D has been isolated. In the present study, the G1217D mutant was characterized physically and biologically in comparison with the parental HM175 43c strain. The G1217D mutant is more sensitive to acid pH and binds more efficiently to human and rat erythrocytes than the parental 43c strain. In a rat model, it is eliminated from serum more rapidly and consequently reaches the liver with a certain delay compared to the parental 43c strain. In competition experiments performed in vivo in the rat model, the G1217D mutant was efficiently outcompeted by the parental 43c strain. Only in the presence of antibodies reacting specifically with the parental 43c strain could the G1217D mutant outcompete the parental 43c strain in serum, although the latter still showed a remarkable ability to reach the liver. Altogether, these results indicate that the G1217D mutation induces a low fitness phenotype which could explain the lack of natural antigenic variants of the glycophorin A binding site.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593170      PMCID: PMC3421636          DOI: 10.1128/JVI.00707-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Development, evaluation, and standardization of a real-time TaqMan reverse transcription-PCR assay for quantification of hepatitis A virus in clinical and shellfish samples.

Authors:  M Isabel Costafreda; Albert Bosch; Rosa M Pintó
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

3.  Hepatitis A virus polyprotein processing by Escherichia coli proteases.

Authors:  Rosa M Pintó; Susana Guix; Juan F González-Dankaart; Santiago Caballero; Gloria Sánchez; Ke-Jian Guo; Enric Ribes; Albert Bosch
Journal:  J Gen Virol       Date:  2002-02       Impact factor: 3.891

4.  A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction.

Authors:  Nicole M Kotchey; Kei Adachi; Maliha Zahid; Katsuya Inagaki; Rakshita Charan; Robert S Parker; Hiroyuki Nakai
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

5.  Experimental hepatitis A virus infection in guinea pigs.

Authors:  B Hornei; R Kämmerer; P Moubayed; W Frings; V Gauss-Müller; A Dotzauer
Journal:  J Med Virol       Date:  2001-08       Impact factor: 2.327

6.  Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family.

Authors:  J J McIntire; S E Umetsu; O Akbari; M Potter; V K Kuchroo; G S Barsh; G J Freeman; D T Umetsu; R H DeKruyff
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

7.  Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA.

Authors:  Robert E Lanford; Zongdi Feng; Deborah Chavez; Bernadette Guerra; Kathleen M Brasky; Yan Zhou; Daisuke Yamane; Alan S Perelson; Christopher M Walker; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

8.  Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor.

Authors:  A Dotzauer; U Gebhardt; K Bieback; U Göttke; A Kracke; J Mages; S M Lemon; A Vallbracht
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid.

Authors:  Lluís Aragonès; Susana Guix; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

10.  Hepatitis a virus vaccine escape variants and potential new serotype emergence.

Authors:  Unai Pérez-Sautu; M Isabel Costafreda; Joan Caylà; Cecilia Tortajada; Josep Lite; Albert Bosch; Rosa M Pintó
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

View more
  9 in total

Review 1.  Murine Models of Hepatitis A Virus Infection.

Authors:  Asuka Hirai-Yuki; Jason K Whitmire; Michael Joyce; D Lorne Tyrrell; Stanley M Lemon
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

2.  COVID-19 and erythrocrine function: The roller coaster and danger.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Hope Onohuean; Gaber El-Saber Batiha
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

3.  Hepatitis A virus adaptation to cellular shutoff is driven by dynamic adjustments of codon usage and results in the selection of populations with altered capsids.

Authors:  M Isabel Costafreda; Francisco J Pérez-Rodriguez; Lucía D'Andrea; Susana Guix; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  Molecular basis of the behavior of hepatitis a virus exposed to high hydrostatic pressure.

Authors:  Lucía D'Andrea; Francisco J Pérez-Rodríguez; M Isabel Costafreda; Nerea Beguiristain; Cristina Fuentes; Teresa Aymerich; Susana Guix; Albert Bosch; Rosa M Pintó
Journal:  Appl Environ Microbiol       Date:  2014-08-08       Impact factor: 4.792

Review 5.  Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.

Authors:  Stephanie E Ander; Frances S Li; Kathryn S Carpentier; Thomas E Morrison
Journal:  PLoS Pathog       Date:  2022-05-05       Impact factor: 7.464

6.  Hepatitis A virus genotype distribution during a decade of universal vaccination of preadolescents.

Authors:  Lucía D'Andrea; Francisco J Pérez-Rodríguez; Montserrat de Castellarnau; Sandra Manzanares; Josep Lite; Susana Guix; Albert Bosch; Rosa M Pintó
Journal:  Int J Mol Sci       Date:  2015-03-25       Impact factor: 5.923

Review 7.  Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication.

Authors:  Mehrdad Ghashghaeinia; Peter Dreischer; Thomas Wieder; Martin Köberle
Journal:  Cell Cycle       Date:  2020-12-11       Impact factor: 4.534

Review 8.  Pathogenicity and virulence of hepatitis A virus.

Authors:  Rosa M Pintó; Francisco-Javier Pérez-Rodríguez; Maria-Isabel Costafreda; Gemma Chavarria-Miró; Susana Guix; Enric Ribes; Albert Bosch
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 9.  Molecular biology and inhibitors of hepatitis A virus.

Authors:  Yannick Debing; Johan Neyts; Hendrik Jan Thibaut
Journal:  Med Res Rev       Date:  2013-05-30       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.